Moussa81/iStock via Getty Images Triple Flag Precious Metals ( TFPM ) up 3.4% in Friday's trading after saying it agreed to acquire a gold stream on the Ravenswood mine in Australia for US$440M in cash. Under the deal terms, Triple Flag ( TFPM ) is entitled to purchase 5.5% of payable gold from the Ravenswood mine under the stream, which steps down to 3.75% after 194.2K oz of gold has been deliver...
Moussa81/iStock via Getty Images Triple Flag Precious Metals ( TFPM ) up 3.4% in Friday's trading after saying it agreed to acquire a gold stream on the Ravenswood mine in Australia for US$440M in cash. Under the deal terms, Triple Flag ( TFPM ) is entitled to purchase 5.5% of payable gold from the Ravenswood mine under the stream, which steps down to 3.75% after 194.2K oz of gold has been delivered, and then to 2.5% after 253K oz of gold have been delivered; the company will make ongoing payments of 10% of the spot gold price for each ounce delivered until 194.2K oz has been delivered, and 20% of the spot gold price thereafter. Ravenswood is one of Australia's 10 largest gold mines by ore reserves, with current proved and probable ore reserves of 147M metric tons at 0.61 g/t containing 2.8M oz of gold. The mine produced 134K oz of gold in 2025 and is expected to produce more than 200K oz/year by 2028 following a recent A$830M investment. Following the addition of Ravenswood, Triple Flag ( TFPM ) increased its 2030 production outlook to 150K-160K gold equivalent oz from 140K-150K GEOs previously. Ravenswood is jointly owned by operator EMR Capital and Golden Energy and Resources. More on Triple Flag Precious Metals Triple Flag: Record Q1, Copper Acquisition, And Insider Buying Are Bullish Signs Triple Flag Precious Metals: Still One Of The Cheapest Streaming Plays In A Gold Supercycle Triple Flag Precious Metals Q1 2026 Earnings Call Presentation
Jonathan Kitchen/DigitalVision via Getty Images Thesis For me, AbbVie Inc. ( ABBV ) is a top-tier pharmaceutical compounder offering the combination of dividend income, pipeline story, and defensiveness in a macro environment of uncertainty. It has managed the most significant pharma revenue loss ever (regarding the Humira patent cliff, in my view) by creating with Skyrizi and Rinvoq a franchise t...
Jonathan Kitchen/DigitalVision via Getty Images Thesis For me, AbbVie Inc. ( ABBV ) is a top-tier pharmaceutical compounder offering the combination of dividend income, pipeline story, and defensiveness in a macro environment of uncertainty. It has managed the most significant pharma revenue loss ever (regarding the Humira patent cliff, in my view) by creating with Skyrizi and Rinvoq a franchise that has now outstripped the maximum sales of Humira. With shares trading at about 14.8 times forward earnings versus the industry (17.7) and management guiding for double digit immunology sales growth out to 2026, I believe the stock deserves a “hold” recommendation for existing holders and a cautious “accumulate on weakness” stance for new buyers. YCharts It is the large debt burden that stops me from assigning a buy recommendation, as this erodes any margin of safety and makes the story very much one of pipeline execution. Company Overview Founded in 2013 as a spin-off from Abbott Laboratories, AbbVie is a biopharmaceutical company dedicated to research, development, manufacturing, and marketing of treatments in the fields of immunology, oncology, neuroscience, and eye care. While one of the newer entrants in the pharmaceutical industry, AbbVie has quickly established itself as the home of its flagship product, Humira, the anti-inflammatory blockbuster generating over $21 billion annually at its peak. Currently, AbbVie is operating around the world with a market capitalization that makes it one of the largest pharmaceutical companies in the world. What sets AbbVie apart operationally is their purposeful strategy of creating a de facto succession of product cycles, instead of having one ‘star’ product that persists for decades. Their commitment to investing in new generations of immunology products has gone hand-in-hand with their move into Oncology through acquisitions, no less than the $10.1 billion buyout of ImmunoGen at the end of 2023. This combination of traditional ...
The S&P 500 Index ($SPX ) (SPY ) is up +0.29%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.37%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.41%. June E-mini S&P futures (ESM26 ) are up +0.28%, and June E-mini Nasdaq futures (NQM26...
The S&P 500 Index ($SPX ) (SPY ) is up +0.29%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.37%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.41%. June E-mini S&P futures (ESM26 ) are up +0.28%, and June E-mini Nasdaq futures (NQM26...
MoMo Productions/DigitalVision via Getty Images About three months ago, in early March of this year, I ended up upgrading shares of Simmons First National Corporation ( SFNC ) from a Sell to a soft Buy. A double upgrade is quite rare for me. But I believed it was justified after management had achieved some rather remarkable improvements on the operational side, including not only the income state...
MoMo Productions/DigitalVision via Getty Images About three months ago, in early March of this year, I ended up upgrading shares of Simmons First National Corporation ( SFNC ) from a Sell to a soft Buy. A double upgrade is quite rare for me. But I believed it was justified after management had achieved some rather remarkable improvements on the operational side, including not only the income statement but the balance sheet as well. The company was exhibiting attractive organic deposit growth and was also experiencing a reduction in brokered and uninsured deposits. Asset quality was also improving as profitability surged. What's more, the stock was priced at levels that made sense, especially in relation to earnings. Since then, shares have risen 6.9%. But this is unfortunately below the 9.5% rise that the S&P 500 ( SP500 ) has exhibited over the same window of time. While this is disappointing, I would say that the market is being a bit irrational here. The firm is certainly not the best candidate out there. And even though asset quality is decent, it is lower than other comparable businesses. However, the stock is priced at levels that are decently attractive. And because of that, combined with continued growth that we are seeing, I believe that maintaining it as a soft buy is appropriate here. Checking in on Simmons First National Corporation The only new data that investors have right now for Simmons First National Corporation covers the first quarter of the company's 2026 fiscal year . Honestly, I would say that the quarter turned out quite positively for the business. Take the balance sheet as an example. Deposits came in at $20.20 billion. That was up slightly from the $20.18 billion that the company had at the end of 2025. One thing that I especially love about the institution is that brokered deposits are quite low. It had about $1.91 billion in brokered deposits. That's 9.5% of the total. For those not familiar, brokered deposits are high-cost deposits borr...
Exports of refined fuels from the Persian Gulf have rebounded this month as more tankers managed to slip through the Strait or Hormuz, providing welcome relief to markets starved of supply. Shipments from countries including Saudi Arabia, the United Arab Emirates and Kuwait averaged more than 600,000 barrels a day so far this month, according to data from research firm Vortexa. That’s an increase ...
Exports of refined fuels from the Persian Gulf have rebounded this month as more tankers managed to slip through the Strait or Hormuz, providing welcome relief to markets starved of supply. Shipments from countries including Saudi Arabia, the United Arab Emirates and Kuwait averaged more than 600,000 barrels a day so far this month, according to data from research firm Vortexa. That’s an increase of about 50% in exports of crucial oil products such as diesel, gasoline and naphtha, compared with April and May. However, it’s still just a fraction of the roughly 4 million barrels a day of fuels those countries were shipping prior to the war. Gulf producers have ramped up shipments of crude and fuels by spiriting tankers out of the Strait of Hormuz under the cover of night with their tracking signals turned off. Qatar’s liquefied natural gas tankers have also been going dark to evade detection and resume flows to buyers. Read: Oil Tankers Go Dark to Sneak More Barrels Through Hormuz In addition to boosting Hormuz shipping flows after months of almost total closure, Gulf countries are also exploring diplomatic approaches to Iran. The UAE’s leaders are seeking a detente with Tehran, which they consider an enemy but realize won’t be dislodged from power, according to people familiar with the matter. Qatar and Saudi Arabia, which have also been hit by Iran and its proxies, are also trying to de-escalate tensions. Price Pressure After two decades of investment in their refineries, Middle Eastern oil producers have become major suppliers of diesel and jet fuel to Europe and Asia. The war choked off most of that flow, hitting industry and throwing aviation into disarray. The recent recovery in exports has helped keep a lid on prices. Brent crude has averaged just over $100 a barrel over the last three months, well short of the $150 or $200 a barrel that some analysts had feared. The international benchmark has fallen below $90 after President Donald Trump called off attacks on...
In early trading on Friday, shares of Arm Holdings topped the list of the day's best performing components of the Nasdaq 100 index, trading up 6.3%. Year to date, Arm Holdings registers a 232.8% gain. And the worst performing Nasdaq 100 component thus far on the day is KLAC, t
In early trading on Friday, shares of Arm Holdings topped the list of the day's best performing components of the Nasdaq 100 index, trading up 6.3%. Year to date, Arm Holdings registers a 232.8% gain. And the worst performing Nasdaq 100 component thus far on the day is KLAC, t
In early trading on Friday, shares of Mosaic topped the list of the day's best performing components of the S&P 500 index, trading up 6.9%. Year to date, Mosaic has lost about 6.4% of its value. And the worst performing S&P 500 component thus far on the day is KLAC, tr
In early trading on Friday, shares of Mosaic topped the list of the day's best performing components of the S&P 500 index, trading up 6.9%. Year to date, Mosaic has lost about 6.4% of its value. And the worst performing S&P 500 component thus far on the day is KLAC, tr
wildpixel/iStock via Getty Images This is my first time covering Eikon ( EIKN ), a Millbrae, California based biotech that completed its Initial Public Offering [IPO ] in February this year, raising ~$381m at ~$18 per share. The IPO was the largest for a biotech since 2024. Eikon's current drug development pipeline (focused primarily on oncology, albeit with preclinical neuroscience programs) look...
wildpixel/iStock via Getty Images This is my first time covering Eikon ( EIKN ), a Millbrae, California based biotech that completed its Initial Public Offering [IPO ] in February this year, raising ~$381m at ~$18 per share. The IPO was the largest for a biotech since 2024. Eikon's current drug development pipeline (focused primarily on oncology, albeit with preclinical neuroscience programs) looks as follows (source: Q1 2026 quarterly report / 10Q submission ): Eikon Therapeutics pipeline (10Q filing) Creating excitement around Eikon is the fact that the biotech's founders are industry veterans who have worked on some of the world's most effective and best-selling cancer drugs - as per the company's 2025 annual report / 10K filing : Our Chair and Chief Executive Officer, Dr. Roger M. Perlmutter, M.D., Ph.D., and our Chief Medical Officer, Dr. Roy Baynes, M.D., Ph.D., together have a proven track record of identifying, developing, and commercializing some of the most impactful drugs ever brought to market, including pembrolizumab, currently the world’s best-selling oncology therapeutic and arguably the most important anti-neoplastic agent ever introduced into clinical practice. Pembrolizumab is better known as Keytruda, the immune checkpoint inhibitor [ICI ] marketed and sold by Merck & Co. ( MRK ), and in 2025, it earned >$30bn in revenues, making it the world's biggest selling cancer drug and the second biggest selling prescription drug, behind only Eli Lilly's tirzepatide, or Mounjaro/Zepbound. As we can see in the table above, two assets have reached the Phase 2 clinical study stage - a TLR7/8 targeting candidate indicated for melanoma and non-small cell lung cancer, both double-digit billion dollar markets, and a PARP1 (Poly ADP-ribose polymerase) inhibitor targeting ovarian, breast, prostate, and pancreatic cancer. Candidates Assessed After Eikon Shares Updates At ASCO Re EIK1011, Eikon notes in its 10K filing : Historically, TLR (toll like receptor) product c...
Royal Ascot-bound stayer will sport them in parade ring and down to start next week owing to eye condition Trawlerman, last year’s winner of the Gold Cup at Royal Ascot, will wear an equine version of “ski goggles” in the paddock and on the way to post before defending the stayers’ crown next Thursday, John Gosden, the gelding’s trainer, revealed on Friday. Speaking on the Nick Luck Daily podcast,...
Royal Ascot-bound stayer will sport them in parade ring and down to start next week owing to eye condition Trawlerman, last year’s winner of the Gold Cup at Royal Ascot, will wear an equine version of “ski goggles” in the paddock and on the way to post before defending the stayers’ crown next Thursday, John Gosden, the gelding’s trainer, revealed on Friday. Speaking on the Nick Luck Daily podcast, Gosden said that the unusual step is necessary because Trawlerman “has a weird problem with his eyes in that he becomes very sensitive to light”. Continue reading...
Looking at the universe of stocks we cover at Dividend Channel, on 6/15/26, Chesapeake Utilities Corp. (Symbol: CPK) will trade ex-dividend, for its quarterly dividend of $0.735, payable on 7/6/26. As a percentage of CPK's recent stock price of $122.45, this dividend works out
Looking at the universe of stocks we cover at Dividend Channel, on 6/15/26, Chesapeake Utilities Corp. (Symbol: CPK) will trade ex-dividend, for its quarterly dividend of $0.735, payable on 7/6/26. As a percentage of CPK's recent stock price of $122.45, this dividend works out
Looking at the universe of stocks we cover at Dividend Channel, on 6/15/26, Nuveen Mortgage Opportunity Term Fund (Symbol: JLS) will trade ex-dividend, for its monthly dividend of $0.1535, payable on 7/1/26. As a percentage of JLS's recent stock price of $17.75, this dividend w
Looking at the universe of stocks we cover at Dividend Channel, on 6/15/26, Nuveen Mortgage Opportunity Term Fund (Symbol: JLS) will trade ex-dividend, for its monthly dividend of $0.1535, payable on 7/1/26. As a percentage of JLS's recent stock price of $17.75, this dividend w
Bonnie Chan, CEO of Hong Kong Exchanges and Clearing Ltd., speaks at the 2026 Caixin Summer Summit in Hong Kong on June 12. Photo: Caixin Average daily northbound trading volume under the Stock Connect program linking the Chinese mainland and Hong Kong has surged to nearly 390 billion yuan ($57 billion) this year, driven by rising foreign investor interest, according to Bonnie Chan, chief executiv...
Bonnie Chan, CEO of Hong Kong Exchanges and Clearing Ltd., speaks at the 2026 Caixin Summer Summit in Hong Kong on June 12. Photo: Caixin Average daily northbound trading volume under the Stock Connect program linking the Chinese mainland and Hong Kong has surged to nearly 390 billion yuan ($57 billion) this year, driven by rising foreign investor interest, according to Bonnie Chan, chief executive of Hong Kong Exchanges and Clearing Ltd. Speaking Friday at the 2026 Caixin Summer Summit in Hong Kong, Chan said average daily northbound trading volume reached a record 212.4 billion yuan in 2025, up 42% from a year earlier. In 2026, daily volume has climbed further, averaging between 380 billion yuan and 390 billion yuan, she said.
Looking at the universe of stocks we cover at Dividend Channel, on 6/15/26, Eaton Vance Risk-Managed Diversified Equity Income Fund (Symbol: ETJ) will trade ex-dividend, for its monthly dividend of $0.0651, payable on 6/30/26. As a percentage of ETJ's recent stock price of $8.3
Looking at the universe of stocks we cover at Dividend Channel, on 6/15/26, Eaton Vance Risk-Managed Diversified Equity Income Fund (Symbol: ETJ) will trade ex-dividend, for its monthly dividend of $0.0651, payable on 6/30/26. As a percentage of ETJ's recent stock price of $8.3